Ophthalmic Pharmaceutical Drugs

Published by: Global Industry Analysts

Published: Apr. 1, 2008 - 523 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. Industry Overview

A Curtain Raiser

Drugs Developed in the Recent Past

What the Future Holds in Store?

Where Does the Opportunity Lie?

In the Shifting Demographics

Which Disease Segment Offers Abundant Opportunities for R&D Initiatives

Leading Companies & Their Areas of Research Interest/Focus

Business Opportunities in Ophthalmology: A Fact Sheet

Impediments in Picking the Ripe & Low Hanging Opportunities

Low Patient Compliance

What’s the Antidote to Low Patient Compliance?

Innovation in Ophthalmic Pharmaceuticals: How Does It Help Patients?

An Unequivocal Discussion About Ocular Drug Design and Delivery

Why Understanding of the Metabolic Activity of the Eye is Important?

Pitfalls of Traditional Ocular Treatment

Ophthalmic Drug Delivery: A Recapitulation of Facts

Antidotes to Low Delivery of Ocular Drugs & High Side Effects

Prodrug

Soft Drugs (SDs)

Soft Corticosteroids

Drug Penetration Enhancers

Chitosan Based Drugs & Drug Delivery Systems

How Chitosan is used to Improve Ocular Drug Retention On the Eye’s Surface?

The Future of Ophthalmic Drug Delivery

A Straight Talk About Ophthalmic Drug Delivery Technologies

High Flying Expectations of Blistering Pace of Drug Development Grounded

First Generation Advancements Made in Ocular Drugs

Second Generation Advancements Made in Ocular Drugs

Limiting Factors

2. Market Dynamics

Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty

Ophthalmic Inserts Flaunt the Potential to Eclipse the Popularity of Eye Drops

Rising Incidences of Glaucoma: A Business Case for Ophthalmic Drugs

Aging Population & Environmental Factors Drive Growth

Increase in Health Care Spending

Opportunities Abound in the Developing Countries

Innovative Products Lend Traction to Growth

Reimbursements: “Under the Umbrella”

Pricing Statistics On Select Ophthalmic Drugs in the United States for the Year 2006

Price Changes for Select Ophthalmic Drugs in the Year 2005

3. An Overview of Ophthalmic Drugs

Anti Viral Drugs

Adenoviral Infections

Herpes Simplex Virus

Herpes Zoster (Varicella Zoster Disease)

Corticosteroids

Loteprednol

Prednisolone

Dexamethasone

Fluorometholones

Fluorometholone Alcohol

Fluorometholone Acetate

Rimexolone

Clinical Efficacy of Steroids

Topical Corticosteroid Drugs

Tapering of Steroid Intake

Non-Steroids Anti Inflammatory Drugs (NSAID)

Use of Topical NSAIDs

Topical & Systemic NSAIDs

Ketorolac: A Potent NSAID

Non-Steroidal Anti-Inflammatory Drugs

Antibiotics

Sodium Sulfacetamide

Sulfisoxazole

Bacitracin

Bacitracin and Polymyxin B: A Powerful Duo

Bacitracin, Polymyxin B and Neomycin: Three To Tango

Trimethoprim with Polymyxin B

Chloramphenicol

Erythromycin

Gentamicin and Tobramycin

Fluoroquinolones

Types of Fluoroquinolones

Ciprofloxacin

Gatifloxacin

Levofloxacin

Moxifloxacin

Ofloxacin

Topical Antibiotic Drugs

Ophthalmic Antihistamines

Azelastine

Emedastine

Epinastine

Ketotifen

Olopatadine

Ophthalmic Mast-Cell Stabilizers

Cromolyn

Nedocromil Sodium

Pemirolast

Drugs to Treat Glaucoma

Beta-Adrenergic Blockers or "Beta Blockers"

Timolol

Levobunolol

Carteolol

Metipranolol

Betaxolol

Alpha-Adrenergic Agonists

Carbonic Anhydrase Inhibitors

Acetazolamide

Dorzolamide

Acetazolamide & Dorzolamide: How Good Is the Combo?

Miotics

Prostaglandins

Mydriatics & Cycloplegics

Side Effects

Over-The-Counter (OTC) Ophthalmic Preparations

Artificial Tears

Lubricating Ointments

Mast Cell Stabilizers

Antihistamines

Phenylephrine

Naphazoline

Xylometazoline

Astringents

Over-The-Counter Ophthalmic Preparations

A Directory Listing of Major Ophthalmic Pharmaceutical Drugs

Formulary Anti- Glaucoma Drugs

Non-Formulary Anti- Glaucoma Drugs

Formulary Topical Anti-Glaucoma Drugs

Formulary Ophthalmic Antiinfective/Corticosteroids Drugs

Non-Formulary Ophthalmic Antiinfective/ Corticosteroids Drugs

Formulary Ophthalmic Corticosteroid Drugs

Non-Formulary Ophthalmic Corticosteroid Drugs

Formulary Ophthalmic Topical Antibacterial Drugs

Non-Formulary Ophthalmic Topical Antibacterial Drugs

Formulary Ophthalmic Topical Antiviral Drugs

Other Ophthalmic Formulary Drugs

Other Ophthalmic Non-Formulary Drugs

New Drugs In the Pipeline

4. Ophthalmic Disorders: A Freeze Frame

The Human Eye: A Remarkable & Intriguing Organ of Sight

The Outer Layer

The Middle Layer

The Inner Layer

Common Ophthalmic Disorders: An Exposition

Cataract

Causes

Types of Cataract

Treatment Strategies

How Widespread is the Disease?

Glaucoma

Who’s At Risk?

Types of Glaucoma

Primary Open Angle Glaucoma (POAG)

Acute Angle-Closure Glaucoma (AACG)

Congenital Glaucoma

Secondary Glaucoma

Treatment Strategies

Anti- Glaucoma Ophthalmic Drugs

How Widespread is the Disease?

Table 1: Prevalence of Glaucoma in the World: Year 1999 and 2006 A Comparison (In 000 Individuals) (includes corresponding Graph/Chart)

Is Marijuana A Potential Cure?

Age-Related Macular Degeneration (AMD)

Types of AMD

Dry AMD (Non-Neovascular)

Wet AMD (Neovascular)

Causes

Treatment Strategies

Nutrition & AMD

Diabetic Retinopathy

Treatment Strategies

How Widespread is the Disease?

Ocular Allergies

Treatment Strategies

Immunotherapy: A Popular Anti-Allergy Treatment Approach

Ocular Inflammation: A Symptom of Ocular Allergies

How Can Allergies Be Prevented?

Conjunctivitis (Pink Eye)

Types of Conjunctivitis

Pathogenesis

Treatment Strategies

Keratitis

Types of Keratitis

Treatment Strategies

Dry Eye

Why Are Tears So Crucial for Normal Eye Health?

What Causes Dry Eye?

Treatment Strategies

Refractive Errors

Causes for Refractive error

Treatment for Refractive Errors

Cost of Treatment

Factors contributing to the Difference in Surgery Costs

5. FDA Regulations and Approvals

Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial

Alimera Conducts Phase III Medidur Trial

ISTA Pharmaceuticals Files NDA for Xibrom™ QD

AzaSite Receives FDA Approval

Alimera Sciences Receives FDA Approval

Alcon Receives Approval for Vegamox™ Ophthalmic Solution in Japan

Alcon Receives Marketing Approval for Patanol® in Japan

Allergan Receives FDA Approval for Lumigan®

Allergan’s Ganfort® Receives Pan European License

Pfizer Receives Approval from EC to Market Macugen®

Akorn Gets Nod for Conducting Clinical Trial of AK-1015

Genentech ‘s Lucentis Receives FDA Approval

MacuSight Receives FDA Approval for IND Application of Sirolimus

Sami Labs Receives Approval for Ocufors

Toyamo and Nidek Obtain Manufacturing Approval for Quinolone Ophthalmic Solutions

Alcon's NEVANAC Receives FDA Approval

Fougera Obtains Approval for MetroGel®

Allergan’s Alphagan P Receives FDA Approval

Santen Obtains Approval for Manufacturing and Marketing PAPILOCK

Alcon Receives FDA Approval for Adding Susceptible Pathogens to VIGAMOX

BOL Receives FDA Approval for Ofloxacin

Hi-Tech Pharmacal Receives FDA Clearance for Ofloxacin Ophthalmic Solution

Vision Blue and DORC International Receives FDA Approval for Trypan Blue

Pfizer Receives FDA Nod for Macugen®

Bausch & Lomb Bags FDA Approval for its Zylet™

Alcon Receives Approval for Olopatadine (Patanol)

Pharmacia Receives FDA Approval for Latanoprost Ophthalmic Solution

US FDA Approves Allergan’s New Acular LS 0.4% for Ocular Pain Reduction

Allergan Obtains FDA Approval for Zymar

6. Product Innovations/Introductions

Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections

Reckitt Benckiser Launches Two Eye Care Products

Alcon Launches DUOTRAV for Glaucoma Treatment

Rohto Pharmaceutical Launches Switch OTC Ophthalmic Drug

Indoco Remedies to Launch Ophthalmic Drugs in America

Akorn Launches Ophthalmic Drug Products

AlphaRx Formulates the Ophthalmic Product, Binoxan™

Alimera Sciences Introduces Online Consumer Ordering Facility

Fougera Adds Two Novel Products to its Ophthalmic Product Line

Micro Vision Launches Anti-Glaucoma Drugs

ISTA Pharmaceuticals Launches Istalol for Glaucoma Treatment in the US

Falcon Unveils Trifluridine Ophthalmic Solution, 1%

Alimera Sciences Unveils Soothe™ Emollient Eye Drops

Novartis Introduces Zaditen in Japan

Falcon Releases Brimonidine Tartrate Ophthalmic Solution, 0.2%

Taiwanese Researchers Introduces Thermosensitive Ophthalmic Drop

Alcon Introduces Systane Lubricant Eye Drops

Allergan Releases Restasis for Dry Eye Treatment

Biosyntrx Launches BioTears

Novartis to Introduce Pirenzepine Ophthalmic Gel

7. Recent Industry Activity

Bausch & Lomb Acquires IOL Maker, Eyeonics

Akorn Inks Manufacture &Supply Agreement for Ophthalmic Solution

CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb

Genaera Corporation Quits Evizon Clinical Trials

Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF) Aptamer Program

Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs

Bausch & Lomb Acquire Soothe Products from Alimera

Froptix, Acuity, eXegenics Merge to Form Opko Corporation

Alimera, Emory Collaborate Over Potential Ophthalmic Treatments Using Novel Antioxidants

Santen Signs Agreement with Vistakon Pharmaceuticals for US Launch of Iquix®

Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections

QLT Takes Over Forsight Newco II, Inc

Phase IV Clinical Trials Of Macugen®

Results Of Phase II Clinical Trials - Macugen®

Macugen® Receives European Regulatory Approval

Bausch & Lomb Purchases OTC Allergy Drugs of Alimera

Phase II Trial of Acuity Pharmaceutical’s Bevasiranib

Advanced Refractive Technologies Acquires a Subsidiary of UTEK Corporation

Sirion Therapeutics Acquires Sytera

Teva Pharmaceuticals Acquires Ivax

Alcon Enters into an Agreement with Amgen

QLT Signs an Agreement with Retinagenix

NicOx Enters into Licensing Agreement with Pfizer

OccuLogix Signs Agreement to Acquire SOLX

ISTA Receives License from Senju for Allergy Treatments

Acuity Receives License for Nchlorotaurine

Akorn and AVR Enter into Commercial Manufacturing & Supply Agreement

Lantibio Signs Agreement with TRB Chemedica

Argentis and Southern College of Optometry Enter into Agreement

Bausch & Lomb Enters into Marketing Agreement with Novartis

Santen Pharmaceuticals and Ube Industries to Develop Glaucoma Therapy Jointly

Santen Pharmaceutical and CytoPathfinder Signs an Agreement

Kalypsys Inks an Agreement with Alcon, Inc

Combination RX Enters into a Collaboration Agreement with Fovea

Par Pharmaceutical Joins Force with Spectrum Pharmaceuticals

Isotechnika Sells Eye Drug Rights to Lux Biosciences

Alimera Sciences Collaborates With CYNACON

Novartis Inks an In-Licensing Agreement with Otsuka

Alimera Sciences Commences Phase III Trials for Medidur™

SurModics Acquires InnoRx

Bausch & Lomb Acquires Shandong Chia Tai Freda Pharmaceutical Group

OSI Pharmaceuticals Takes Over Eyetech Pharmaceuticals

Pfizer Acquires Angiosyn

Bausch & Lomb Collaborates with PTC Therapeutics

AMRI Enters into Research Collaboration with Alcon

Bausch & Lomb Bags License from Cephalon

PediaMed and Allergan Sign a Co-Promotion Agreement

SurModics Bags Option to Acquire Exclusive Rights from Rutgers University

Sankyo Co. and Santen Pharmaceutical Sign Agreement

Acuity Pharmaceuticals Enters into Agreement with Intradigm Corporation

Apotex Inks Marketing Agreement with Akorn

Novartis Enters into an Agreement with Senju Pharmaceutical

Novartis Strikes a Licensing Deal with Otsuka Pharmaceutical

Custom RX recalls Trypan Blue 0.06% Ophthalmic Solution

AMO Takes Over VISX

Advanced Medical Optics Acquires Ophthalmic Surgical Business of Pfizer

Santen to Take Over Marketing Rights of Rescula from R-Tech Ueno

Alimera Sciences Inks Co-promotion Agreement with VISTAKON Pharmaceuticals

Akorn Inks a Purchase and Supply Agreement with FDC

ISTA Pharmaceuticals Receives Marketing License From Senju Pharmaceuticals

Pfizer Inc Acquires Pharmacia Corp

Allergan Takes Over Oculex Pharmaceuticals

Allergan Enters into an Agreement with Acadia

8. Focus on Select Global Players

Akorn, Inc. (USA)

Alcon Eye Care, Inc. (USA)

Allergan, Inc. (USA)

Alimera Sciences, Inc. (USA)

Bausch & Lomb, Inc. (USA)

Genvec, Inc. (USA)

GlaxoSmithKline Plc (UK)

Inspire Pharmaceuticals, Inc. (USA)

ISTA Pharmaceuticals, Inc. (USA)

Merck & Co., Inc. (USA)

Novartis Ophthalmics (Canada)

Opko Health, Inc (USA)

Otsuka Pharmaceutical Co., Ltd. (Japan)

Pfizer Inc. (USA)

QLT, Inc. (Canada)

Santen Pharmaceutical Co. (Japan)

Santen Inc. (USA)

9. Global Market Perspective

Table 2: World Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 3: World Long-term Projections for Ophthalmic Pharmaceutical Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 4: World 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Table 5: World Recent Past, Current and Future Analysis for Glaucoma by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 6: World Long-term Projections for Glaucoma by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 7: World 10-Year Perspective for Glaucoma by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Table 8: World Recent Past, Current and Future Analysis for Anti-allergy by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 9: World Long-term Projections for Anti-Allergy by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 10: World 10-Year Perspective for Anti-allergy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Table 11: World Recent Past, Current and Future Analysis for Anti-infective by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 12: World Long-term Projections for Anti-Infective by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 13: World 10-Year Perspective for Anti-infective by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Table 14: World Recent Past, Current and Future Analysis for Dry Eye by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 15: World Long-term Projections for Dry Eye by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 16: World 10-Year Perspective for Dry Eye by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Table 17: World Recent Past, Current and Future Analysis for Anti-inflammation by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 18: World Long-term Projections for Anti-Inflammation by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 19: World 10-Year Perspective for Anti-inflammation by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Table 20: World Recent Past, Current and Future Analysis for Back of Eye by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 21: World Long-term Projections for Back of Eye by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 22: World 10-Year Perspective for Back of Eye by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Table 23: World Recent Past, Current and Future Analysis for Other Treatment Category by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 24: World Long-term Projections for Other Treatment Category by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 25: World 10-Year Perspective for Other Treatment Category by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

A. Market Analysis

Outlook

Emphasis on Greater Awareness About Ophthalmic Disorders

Growth Drivers In a Capsule

Impediments to Growth

Market Fact Sheet

Glaucoma Market: A Primer

Awareness Among Patients

High Costs

Treatment Patterns Adopted By Doctors

The All Consuming Issue of Compliance

Drug Brands & Their Patience Compliance Scores

Market Share Statistics

The New Batting Order

Table 26: The US Market for Ophthalmic Pharmaceutical Drugs (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Allergan, Novartis Pharmaceutical, Pfizer/OSI Pharmaceuticals, Bausch & Lomb Pharmaceuticals, and Others (includes corresponding Graph/Chart)

Table 27: Top 10 Brands of Eye/Lens Care in the US: Breakdown of Dollar and Unit Sales Through Drug Stores, Supermarkets and Discount Stores For the Year Ended November 2007 (In US$ 000 and Thousand Units)

Table 28: Top 5 Eye Care Products in the US: Breakdown of Dollar Sales Through Food, Drug and Mass Market Channels for the Year Ended July 2007 (In US$ Million) (includes corresponding Graph/Chart)

Table 29: Age-Related Wet Macular Degeneration Market in the United States (2004-2006): Percentage Market Share Breakdown of Leading Players - QLT Inc/Novartis Pharmaceutical Corp, and Eyetech Pharmaceuticals (OSI) / Pfizer

Table 30: Ocular Allergy Market in the United States (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Novartis Pharmaceutical, Bausch & Lomb Pharmaceuticals, Allergan, Santen, and Others (includes corresponding Graph/Chart)

Table 31: Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs) Market in the United States (2005 & 2006): Percentage Market Share Breakdown of Leading Players - Allergan, Inc. Novartis Pharmaceutical Corp., Alcon Laboratories, Inc., and ISTA Pharmaceuticals (includes corresponding Graph/Chart)

Table 32: Age-Related Macular Degeneration Market in the United States (2006, 2009 & 2012): Dollar Sales of Major Branded Drugs - Visudyne, Macugen, and Lucentis (In US$ Million) (includes corresponding Graph/Chart)

Age-Related Macular Degeneration Market in the United States (2006) - New Brands Expected to hit the Market

Update On Drugs & Their Manufacturers in the US

Patent Expirations of Key Ophthalmic Product Brands in the United States

Major Anti-Glaucoma Drugs Available in the United States: Year 2006

Major Drugs Available in the United States for the Treatment of AMD: Year 2005

Drugs in the Pipeline for the Treatment of AMD in the United States: Year 2005

Major Drugs Available in the United States for the Control of Dry Eye: Year 2005

US Market for Dry Eye: Drugs in the Pipeline Year 2005

Companies Actively Involved in Manufacturing Drugs for Dry Eye: Year 2005

Major Drugs Available in the United States for the Treatment of Ocular Allergies: Year 2005

US Market for Ocular Allergies: Drugs in the Pipeline: Year 2005

Statistical Findings On Ophthalmic Diseases in the United States

Table 33: Prevalence of Age-Related Macular Degeneration: Percentage Breakdown by Wet AMD & Intermediate Dry AMD by Age Group for the Year 2005 (includes corresponding Graph/Chart)

Table 34: Prevalence of Age-Related Wet Macular Degeneration in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)

Table 35: Number of Individuals Treated for Wet AMD in the United States (In Thousands) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart)

Table 36: Prevalence of Ocular Hypertension (OHT) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart)

Table 37: Prevalence of Primary Open Angle Glaucoma (POAG) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart)

Table 38: Prevalence of Normal Tension Glaucoma (NTG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart)

Table 39: Prevalence of Exfoliative Glaucoma (EG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart)

Table 40: Prevalence of Pigmentary Glaucoma (PG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart)

Table 41: Number of Individuals Treated for Glaucoma in the United Sates (2006, 2009 and 2011): Breakdown by Type - Ocular Hypertension (OHT), Primary Open Angle Glaucoma (POAG), Normal Tension Glaucoma (NTG), Pigmentary Glaucoma (PG) and Exfoliative Glaucoma (EG) (In 000 Individuals) (includes corresponding Graph/Chart)

Table 42: Prevalence of Ocular Allergy in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)

Table 43: Number of Individuals Treated for Ocular Allergy in the United States (In Million) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart)

Table 44: Prevalence of Cataract in the United States: Percentage Breakdown by Age Group for the Year 2005 (includes corresponding Graph/Chart)

Table 45: Prevalence of Cataract in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)

Table 46: Number of Individuals Treated for Cataract With Ocular NSAIDs (Topical Non- Steroidal Anti-Inflammatory Drugs) in the United States for the Years 2006, 2009 & 2012 ((In Millions) (includes corresponding Graph/Chart)

Table 47: Prevalence of Dry Eye in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)

Table 48: Number of Individuals Treated for Dry Eye in the United States (In 000s) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart)

FDA Approvals

Product Launches

Strategic Corporate Developments

Key Players

B. Market Analytics

Table 49: US Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 50: US Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 51: US 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

2. Canada

A. Market Analysis

Outlook

Lack of Awareness: A Key Issue

Key Players

Strategic Corporate Developments

B. Market Analytics

Table 52: Canadian Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 53: Canadian Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 54: Canadian 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

3. Japan

A. Market Analysis

Outlook

Growth Drivers

Market Data Statistics

Leading Ophthalmic Pharmaceutical Brands In the Market

Table 55: Japanese Market for Prescription Ophthalmic Drugs: Percentage Breakdown by Therapeutic Area - Glaucoma, Infection, Corneal Disorder, Ocular Allergy, Surgical Preparation, Steroid, Cataract, and Others. (includes corresponding Graph/Chart)

Product Launches

Strategic Corporate Developments

Key Players

B. Market Analytics

Table 56: Japanese Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 57: Japanese Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 58: Japanese 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4. Europe

A. Market Analysis

Outlook

A Market Primer

Drug Reimbursement in Europe

Key Player

B. Market Analytics

Table 59: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Country/Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 60: European Long-term Projections for Ophthalmic Pharmaceutical Drugs by Country/Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 61: European 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Country/Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Table 62: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 63: European Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 64: European 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4a. France

A. Market Analysis

Outlook

Strategic Corporate Development

B. Market Analytics

Table 65: French Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 66: French Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 67: French 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4b. Germany

Market Analysis

T

able 68: German Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 69: German Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 70: German 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

A. Market Analysis

Outlook

Key Player

B. Market Analytics

Table 71: UK Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 72: UK Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 73: UK 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Market Analysis

Table 74: Italian Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 75: Italian Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 76: Italian 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

A. Market Analysis

Outlook

How & Why the Health Insurance System in Spain is Conducive?

Pharmaceutical Reimbursement Reforms in Spain (1996-2002)

B. Market Analytics

Table 77: Spanish Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 78: Spanish Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 79: Spanish 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

A. Market Analysis

Outlook

Product Launch

Strategic Corporate Development

B. Market Analytics

Table 80: Rest of Europe Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 81: Rest of Europe Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 82: Rest of Europe 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

A. Market Analysis

Outlook

Product Launch

Strategic Corporate development

B. Market Analytics

Table 83: Asia-Pacific Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 84: Asia-Pacific Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 85: Asia-Pacific 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Market Analysis

Table 86: Latin American Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 87: Latin America Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 88: Latin American 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

A. Market Analysis

Outlook

Strategic Corporate Development

B. Market Analytics

Table 89: Rest of World Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 90: Rest of World Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 91: Rest of World 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.